Memorial Sloan-Kettering Cancer Center Cohort: DFS and OS.
Janjigian YY et al. Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. J Thorac Oncol 2011;6(3):569–575.